Hong Kong Trade Development Council of Wanchai, Hong Kong at MEDICA 2020 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Hong Kong Trade Development Council

38/F, Office Tower, Convention Plaza 1 Harbour Road, Wanchai, Hong Kong
Hong Kong, China SAR
Telephone +49 69 95772-0
Fax +852 28240249
frankfurt.office@hktdc.org

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is main exhibitor of

Media files

Contact

Oliver Ehrhardt

Business Matching Assistant

Kreuzerhohl 5-7
60439 Frankfurt/Main, Germany

Email
oliver.ehrhardt@hktdc.org

Elisabeth Steinacher

Marketing Manager

Kreuzerhohl 5-7
60439 Frankfurt/Main, Germany

Email
elisabeth.steinacher@hktdc.org

Visit us

Unsettled / NN

16.11.2020

Topic

all-day

Welcome to meet our Pavilion Exhibitors

Company Name: 1MASKS BY SPRO
Email: cyruswsk@gmail.com
Website: www.1masks.com

Company Name: China Effort Limited
Email: marketing@chinaeffot.com
Website: www.medstar.com.hk

Company Name: East Gear (International) Corp Ltd
Email: info@eastgear-int.com
Website: www.eastgear-int.com

Company Name: Global Info Limited
Email: info@hkglobalinfo.com
Website: www.hkglobalinfo.com

More Less

Our range of products

Product categories

Our products

Product category: Associations and organisations

Meet our Pavilion Exhibitors

Company Name: 1MASKS BY SPRO
Email: cyruswsk@gmail.com
Website: www.1masks.com
Product(s): Masks

Company Name: China Effort Limited
Email: marketing@chinaeffot.com
Website: www.medstar.com.hk
Product(s): Rehabilitation equipment and devices Other equipment and devices for physiotherapy and orthopaedic

Company Name: East Gear (International) Corp Ltd
Email: info@eastgear-int.com
Website: www.eastgear-int.com
Product(s): E-gear QD Touriquet Puch and FASTres Casualty Pouch

Company Name: Global Info Limited
Email: info@hkglobalinfo.com
Website: www.hkglobalinfo.com
Product(s): Isolation Gown, Overall, Gloves, Face Shield, Goggles, Safety Footwear, Face Mask, Respirator, Thermometer

More Less

Product category: Associations and organisations

HONG KONG Asia's Innovation and Technology Hub

With strong and expanding Technological Infrastructure, international and Chinese mainland connection, vibrant talent pool and mature capital market, Hong Kong's innovation ecosystem is developing fast.

More Less

Product category: Associations and organisations

BIO TESTING

Hong Kong is the world’s logistics epicentre and a commercial paradise, making it the perfect base for biotech company Vitargent. Using the embryos of medaka and zebrafish, Vitargent can quickly screen potential toxic products including food and cosmetics and can detect over 1,000 known toxic chemicals. With every test done, Vitargent is building a more comprehensive biotoxicity database for thousands of existing products in the marketplace.

Formed as a result of a university research project, Vitargent has won multiple scientific awards, including the Grand Prix at the 43rd International Exhibition of Inventions of Geneva.

Vitargent is making the world a safer place. Thanks to Hong Kong’s trailblazing technology, consumers enjoy safer products and better lives.

More Less

Product category: Associations and organisations

BIONIC RECOVERY

Medal-winning table tennis player Lee Ming Yip has a secret weapon he uses to prepare for matches: the Hand of Hope. Developed by Rehab-Robotics, with funding provided by the Hong Kong Innovation and Technology Fund, the Hand of Hope helps stroke patients like Lee regain their strength.

The Hand of Hope detects and processes the patient’s own muscle signals. The mechanical hand brace assists the patients to perform desired movements like hand opening and closing. Repetitive training exercises the brain and promotes neuroplasticity.

The Hand of Hope is helping stroke patients take control of their rehabilitation. Thanks to Hong Kong’s commitment to innovation and technology, imagine how their lives will change.

More Less

Product category: Associations and organisations

BONE CONDUCTION

Screens are everywhere: in our pockets, on our desks, in our homes. Wouldn’t it be great to take a little break from them? Hong Kong Cyberport incubatee Origami Labs thinks so. With help from backers the world over, they have developed the ORII Smart Ring, which turns your finger into a smartphone by truly putting voice assistant where it is most useful to you.

Co-founder Kevin Johan Wong is instrumental in the development of this unique bone conduction technology to deliver sound. He believes that ORII Smart Ring not only provides the visually impaired with a better way to stay connected but also inspires us to interact effortlessly with our digital world.

ORII is changing how we communicate with the people around us. Thanks to Hong Kong’s culture of innovation and advancement, this small, wearable device is championing the spirit of the screen-free revolution.

More Less

Product category: Associations and organisations

HEALTH MONITORING

Getting a good night’s sleep could now be as easy as wearing a smart ring developed by Hong Kong–based Belun Technology. For sufferers of sleep apnea, quality sleep is nearly impossible without treatment, and the pre-screening process to reach a diagnosis can be stressful and cost prohibitive. Recognising this, researchers developed the Belun Ring, a medical-grade, wearable device that uses artificial intelligence and bio-sensing technology to monitor and analyse sleep health data at home. The multi-award-winning Belun Ring provides users and medical teams with the ability to monitor and improve sleep apnea – a cloud-based solution that saves time, money and stress. Belun Ring is the guardian of your sleep. Thanks to Hong Kong’s emerging medical and healthcare technologies, imagine how the world will become better and healthier.

More Less

Product category: Associations and organisations

MYOPIA CONTROL / OPTICAL TREATMENT

Retinal diseases in children is on the rise, in part due to overuse of hand-held electronic devices. A local technology start-up Vision Science and Technology Company Limited has successfully commercialised the world’s first myopia-control contact lens specifically designed for children based on the technology from the Hong Kong Polytechnic University.

Moving from lab to market, countless children  benefit from this multi-award-winning patented technology. The Defocus Incorporated Soft Contact (DISC) lens is a multi-zone soft contact lens that projects out-of-focus images onto the retina, effectively reducing the rate of myopic eye growth.

DISC technology is the protector of children with myopia. Thanks to Hong Kong’s research and commercialsation capacity, this tiny lens is granting a clear and bright future for many.

More Less

Company news

Date

Topic

Download

Oct 28, 2020

Hong Kong Starts-up: “Made in Hong Kong” Helps Instill Consumer Trust

With people today living longer, the demand for medical and healthcare products is rocketing, and the prospects for the industry are growing even brighter in the wake of the Covid-19 outbreak, as consumers attach greater importance to their health. Belun Technology Co Ltd (Beluntech), a medical device supplier founded in 2016 by two young local researchers, focuses on developing medical devices and artificial intelligence (AI) systems for monitoring various chronic diseases. Its Chief Executive Officer Lydia Leung talked to HKTDC Research about why the company insisted on establishing its production line in Hong Kong, and about how the coronavirus pandemic has brought about new opportunities. She also discussed the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), which she hopes will lead to increasing alignment in medical device regulations between the mainland and Hong Kong, which will in turn boost the development of the Hong Kong medical market.
Made in Hong Kong

Belun® Ring, Beluntech’s flagship product, is a device for monitoring sleep health. When users wear the ring on a finger while asleep, the device collects all kinds of health data, including the user’s blood oxygen saturation level and pulse rate. Through AI cloud computing technology, a full report on the user’s sleep health can be compiled for diagnosis by a doctor and used to treat sleep disorders such as apnea and insomnia. Belun® Ring is currently the only medical-grade ring device on the market which is approved by the US’s Food and Drug Administration (FDA). Beluntech has obtained ISO 13485 certification for quality management systems for medical devices, and has more than 20 pending patent applications in different markets.

Belun® Ring is made in Hong Kong, which is one of its major selling points. Leung recalled meeting overseas clients at an exhibition who were particularly concerned with where medical devices were manufactured and specifically demanded products made in Hong Kong. She realised that the label “Made in Hong Kong” was effectively an assurance of quality and that clients were willing to pay a premium to buy Hong Kong-made products. Because of this, Beluntech was determined to build its production line in Hong Kong despite the high production costs involved.


Effect of Covid-19

Looking back over the past few years, Leung pinpointed two important milestones in Beluntech’s development. In 2018, the company obtained FDA approval which paved the way for its products to make an entry into the medical device market. Then last year, Beluntech achieved a breakthrough in AI computing that enhanced the precision of its products and greatly increased the confidence of medical professionals in its products.

This year, with the onset of Covid-19, a number of US clients who wanted to use Belun® Ring to monitor the health conditions of coronavirus patients approached the company. Beluntech successfully developed and built a system for this purpose. The Hong Kong government was also eagerly seeking coronavirus treatment solutions, and through the Office of the Government Chief Information Officer (OGCIO), the company made contact with the Hospital Authority (HA). The HA has conducted trials using Belun® Ring for tele-monitoring, and there are now plans that in the event of an acute shortage of hospital beds due to a massive surge in coronavirus cases, hospitals will be able to make use of Beluntech’s system to monitor the conditions of patients isolating at home. The pandemic has prompted people to reconsider the importance of distance health monitoring and the development of intelligent hospitals. It is believed that the market will be devoting more resources to these two areas.

Currently, Beluntech’s clients are mainly clinics, hospitals, insurance companies, healthcare centres and other commercial organisations. The company is making preparations to enter the Taiwan market, with plans to set up an office there to conduct sales and R&D. Describing Beluntech’s hopes to expand to the US, European and South-east Asian markets in the future, Leung said: “We have an expert team well-versed in the relevant regulations in Hong Kong and countries around the world. This is definitely our competitive edge.” However, in a business environment coloured by China-US trade frictions, Leung admitted that the company’s growth hinges very much on whether Hong Kong can maintain its position in the international market.
Biotech R&D 


Beluntech is still in its early growth stage and still has to do a great deal of preliminary work before making a foray into the medical market - developing product prototypes, establishing back-end connections with pharmaceuticals manufacturers and insurance companies, and publishing medical papers in order to win the confidence and approval of the medical field. Leung pointed out that the development cycle of biotech start-ups usually lasts about five to 10 years. The biggest hurdle to growth in that cycle is usually a shortage of funds in the seeding stage. Fortunately, Beluntech managed to raise seed funding successfully through friends and overseas networks.

During its seeding stage, Beluntech did not apply for any government funding as it was wary that the process of acquiring the funds would take too long. Many start-ups with limited resources have inevitably been put off by the complicated application procedures involved. Commenting on the time it takes to secure government funding, Leung joked: “By the time government funding is granted, the technology in question is no longer innovative! This does indeed stifle the development of start-ups.”

The only government funding programme Beluntech has applied for is the STEM Internship Scheme under the Innovation and Technology Fund. The scheme is designed to help innovation and technology (I&T) companies employ interns. Because the launch of the scheme this year coincided with the pandemic, however, it’s still to be seen how effective it will prove to be.

Currently, medical institutions in Hong Kong tend not to use I&T products which have been developed locally, which explains why the medical technology industry is still at an early stage in Hong Kong’s start-up ecosystem. Leung noted that many Hong Kong companies are willing to use new technologies, but because of a lack of confidence, their managers tend to use leading brands so that they aren’t held totally responsible in the event of something going wrong. Leung hopes that the government will introduce more long-term policies to propel full-scale development of the I&T ecosystem, pointing out that the Hong Kong government could learn from its Singaporean counterpart, which has built a diverse entrepreneurship culture and created an environment conducive to risk-taking. Leung added that the medical field in Hong Kong is facing a dire shortage of talent, making it difficult for biotech start-ups to seek professional opinions locally. Employing talent from overseas is an option but it incurs high salary and housing allowance costs, expenses that start-ups can’t possibly afford. This explains why up to now Beluntech has only employed one overseas member of staff.

Beluntech has been given support all along by the Hong Kong Science Park and the Hong Kong Trade Development Council (HKTDC). The four-year Incu-Bio Programme launched by Science Park provides the company with a well-equipped business venue and marketing support, helps it connect with potential investors, clients and the media, and offers match funding. HKTDC has been helping Beluntech develop overseas markets and providing it with opportunities to gain exposure in the local media and through participation in overseas trade fairs. The Chinese University of Hong Kong (CUHK) is another organisation supporting Beluntech, helping the company acquire clinical data. Leung noted that senior CUHK executives had put her in contact with professors in the Faculty of Medicine, who offered valuable advice to the company on clinical trials.
Greater Regulatory Convergence

To Hong Kong’s biotech sector, the GBA is a huge market. Under the plans announced by the central government last year, designated Hong Kong-backed medical institutions in mainland GBA cities are allowed to use drugs and general medical devices registered in Hong Kong. Leung commented that this is good news for medical start-ups in Hong Kong because it usually takes a long time for medical devices to obtain certification in the mainland.

However, before such products can enter the mainland market, many challenges still have to be overcome, such as differences in work flows, rules and regulations, and culture. The mainland’s medical and healthcare market is very different from that of Hong Kong, with a huge government-led medical system dominated by public hospitals, and private hospitals and clinics in the minority. Hong Kong companies need to devote a great deal of resources into trying to gain an understanding of the mainland market environment and cope with its policies. Beluntech cannot currently afford to do this and so has no plans yet for expanding its business into the GBA.

Nevertheless, Leung believes that Hong Kong’s medical market will stand to benefit from the developments in synergy in the GBA. Because mainlanders’ demand for medical services is immense and they have confidence in Hong Kong’s medical system, many of them have for years been coming to Hong Kong to use private medical services. Leung thinks that the SAR government should try to replicate the Hong Kong medical system in the mainland using the GBA as a test bed. Attempts could be made to integrate the work flows in the two places, beginning with the relevant rules and regulations. Although Hong Kong does not currently have any specific rules in place governing the supply of medical devices in the local market, the government has been working on building a regulatory framework. The Hong Kong Medical and Healthcare Device Industries Association (HKMHDIA) has lobbied the Hong Kong government to negotiate with the GBA on integrating the relevant rules and regulations of the two places so that any future medical device regulations can apply to both the mainland and Hong Kong. Once this becomes a reality, it is likely to attract a great number of overseas medical technology companies interested in the GBA market to Hong Kong, so that they can establish a foothold here. This will create a fresh round of opportunities for the Hong Kong medical industry.

More Less

About us

Company details

The Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels.

For more information, please visit: www.hktdc.com/aboutus.
Follow us on Twitter @hktdc and LinkedIn.

More Less

Company information as a PDF file